Hofman MS, et al. - Researchers assessed the safety, efficacy, and effect on quality of life of lutetium-177 [¹⁷⁷Lu]-PSMA-617 (a radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA) enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer) in men (aged 18 years and older) with metastatic castration-resistant prostate cancer and progressive disease after standard treatments. Eligible patients had progressive disease defined by imaging (according to Response Evaluation Criteria In Solid Tumours [RECIST] or bone scan) or new pain in an area of radiographically evident disease, and were required to have an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or lower. In this patient population, high response rates, low toxic effects, and reduction of pain were induced by radionuclide treatment with [¹⁷⁷Lu]-PSMA-617.